Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
about
Genetic selection for protein solubility enabled by the folding quality control feature of the twin-arginine translocation pathway.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.NY-ESO-1 immunotherapy for multiple myeloma.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.PEGylation and its impact on the design of new protein-based medicines.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Inducing efficient cross-priming using antigen-coated yeast particles.Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.Detection and expression analysis of recombinant proteins in plant-derived complex mixtures using nanoUPLC-MS(E).Vaccine and immune cell therapy in non-small cell lung cancer.Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
P2860
Q33232877-9BCFF798-B7A6-4861-956C-9CF8180A06AEQ34111757-50FF9386-E9F7-430C-80BE-4E3A7940DD6AQ34412732-74EDD662-3088-478B-8477-E4960F469758Q34627677-E0AC7144-FFC6-44D7-AD68-2A812F5CF67DQ36637651-8E82AF59-A778-4CF8-B708-B3E9868E8E1FQ37762274-AEB2D9B0-BE97-49F0-AE76-040DC4B4A50DQ38269324-ED5C103A-2CD6-4C00-9D99-CEF13191D333Q39150340-EA41C53A-6C0D-4470-97BA-1181C4D06FF2Q41822345-F2869AD1-187B-4894-9098-371CAC85BAF1Q44545688-230C62B4-5CB9-4047-886E-6CE3C6BB4A0DQ44916488-C7E324F1-A67D-4EBF-90D8-54F0C6EB4D27Q55284807-51DFD6D6-A888-4644-AF8D-F2376844E714Q57571845-62C49261-EF87-4E05-B223-9FB94503583C
P2860
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@en
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@nl
type
label
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@en
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@nl
prefLabel
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@en
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@nl
P2093
P2860
P356
P1476
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
@en
P2093
Cartwright G
Hoffman EW
P2860
P304
P356
10.1081/PB-200054732
P577
2005-01-01T00:00:00Z